Signaling Gateway - 1 August 2008
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0M40EV
*********************************************************************
Signaling Update is a one-stop online resource designed to keep you
in touch with the latest and most exciting research in cell
signaling. New content is uploaded every Friday.
*********************************************************************
In Signaling Update this week:
------------------------
Featured Article
------------------------
IMMUNOLOGY: ARRESTIN CYTOTOXIC PATHWAY ACTIVATION
[beta]-arrestin 2 negatively regulates natural killer (NK) cell
cytotoxicity by facilitating recruitment of Src homology-containing
tyrosine phosphatases (SHPs) to inhibitory NK cell receptors.
Original research paper: Nature Immunology 9, 898-907 (2008)
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0vP0Ee
------------------------
Molecule Pages
------------------------
The Molecule Pages - A comprehensive, relational, signaling database.
Each week we highlight an expert-authored, peer-reviewed Molecule Page.
Wnt10b
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0B2Ba0Ez
WNT family members are lipid-modified secreted glycoproteins
implicated in embryogenesis, adult-tissue homeostasis and
carcinogenesis. Wnt10b activates the canonical WNT signaling cascade
through Frizzled family receptors and LRP5/LRP6 co-receptors. Mouse
Wnt10b is upregulated in mammary tumors associated with mouse mammary
tumor virus (MMTV) infection, and human WNT10B is expressed or
upregulated in various types of tumors.
Adrenergic receptor alpha 2a
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0B2Bb0E1
CLEC-2
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0B2Bc0E2
Search the molecule pages
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0BUuz0Eq
-------------------
Selected Updates
-------------------
CELL SIGNALLING: AKTING IN WNT PATHWAY
Nucleo-cytoplasmic trafficking of [beta]-catenin is regulated by the
formation of a trimolecular complex between itself and the proteins
14-3-3 and Chibby.
Original research paper: J. Cell Biol. 181, 1141-1154 (2008)
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0B2Bd0E3
ANGIOGENESIS: SURVIVAL OF THE INFECTED
Kaposi sarcoma-associated herpes virus (KSHV) infection confers a
survival and angiogenic advantage to endothelial cells by activating
the PI3K-Akt-mTOR pathway.
Original research paper: Cancer Res. 68, 4640-4648 (2008)
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0B2Be0E4
SPECTROSCOPY: SURVIVING THE GAS PHASE
Researchers have identified experimental conditions that permit
membrane-bound protein complexes to survive the gas phase of mass
spectrometry, thus enabling studies into protein topology, subunit
stoichiometry and ligand binding.
Original research paper: Science 321, 243-246 (2008)
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0B2Bf0E5
More Updates:
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0vO0Ed
------------------------
Research Library
------------------------
BLOCKING VEGFR-3 SUPPRESSES ANGIOGENIC SPROUTING AND VASCULAR
NETWORK FORMATION
Nature 454, 656-660 (2008)
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0B2Bg0E6
REGULATION OF TORC1 BY Rag GTPases IN NUTRIENT RESPONSE
Nature Cell Biology 10, 935-945 (2008)
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0B2Bh0E7
AN INTEGRATED PLATFORM OF GENOMIC ASSAYS REVEALS SMALL-MOLECULE
BIOACTIVITIES
Nature Chemical Biology 4, 498-506 (2008)
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0B2Bi0E8
------------------------
Signaling News
------------------------
NATURE REVIEWS CANCER: FOCUS ON TARGETING ANGIOGENESIS
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0B2Bj0EA
The identification and validation of agents that modulate tumor
angiogenesis remains an important area for cancer research. Nature
Reviews Cancer presents a focus issue on targeting angiogenesis with
review articles highlighting the modes of resistance to anti-angiogenic
therapy, the role of integrins in angiogenesis and lymphangiogenesis,
and the mechanisms by which VEGF-targeted therapies inhibit tumor
growth.
More News
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0Crw0EM
-------------------------
Gateway Updates
-------------------------
NATURE PRECEDINGS: PRE-PUBLICATION RESEARCH AND PRELIMINARY FINDINGS
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0BVUp0EB
Nature Precedings is a place for researchers to share pre-publication
research and other scientific documents. Recent posts to Nature
Precedings include the pre-print manuscript entitled:
A coordinated phosphorylation cascade initiated by MSK1 directs RAR
alpha recruitment to target gene promoters
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0B2Bk0EB
And a collection of technical reports on gene expression data from the
Allen Institute for Brain Science
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0B2Bl0EC
Search for documents or browse by subject category to stay informed of
the latest pre-publication research in your field.
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0B2Bm0ED
-----------------------------
Signaling Job of the Week
-----------------------------
Postdoctoral Fellow
Employer: Wellcome Trust Sanger Institute
Location: Hinxton, UK
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0B2Bn0EE
A postdoctoral position is available at the Wellcome Trust Sanger
Institute. The project aims to identify novel human extracellular
receptor-ligand interactions by screening protein libraries of cell
surface receptors from differentiated human blood cells, vascular
endothelium and pathogens. Applicants should have experience in
either high throughput screening, recombinant protein technologies
or cellular immunological assays.
More Jobs:
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0BnjC0EB
To advertise a job in this spot, please contact Naturejobs.
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0vqs0E7
======================================================================
Genentech is proud to be a corporate sponsor of the UCSD-Nature Signaling Gateway.
Genentech is a leading biotechnology company that discovers,
develops, manufactures and commercializes biotherapeutics
for significant unmet medical needs. Fifteen of the currently
approved biotechnology products stem from or are based on
Genentech science. Genentech manufactures and commercializes
ten biotechnology products directly in the United States.
The company has headquarters in South San Francisco, California,
and is traded on the New York Stock Exchange under the symbol DNA.
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0dIO0EY
=====================================================================
As a registered user of the Nature Publishing Group web sites, you
were selected to receive this message in the genuine belief that it
would be of interest to you.
If you no longer wish to receive news and announcements from Nature
Publishing Group or wish to unsubscribe from the Signaling Update
email alert please update your online Nature.com account details here:
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0BCGZ0EG
For further technical assistance or any other enquiries, please click here:
http://ealerts.nature.com/cgi-bin24/DM/y/emdi0Xztnp0H2W0mg0Es
Nature's world-wide offices:
London . Paris . Munich . New Delhi . Tokyo . Melbourne . San Diego .
San Francisco . Washington . New York . Boston
(c) 2008 Nature Publishing Group
---------------------------------------------------------------------
